
Committee XIII
Male Sexual Dysfunction
Prof. Abdel Rahman M. Zahran, MD Professor of Urology, Faculty of Medicine, Alexandria University
Prof. Ahmed El Taher, MD Professor of Urology, Faculty of Medicine, Assuit University
Prof. Emad A. Salem, MD Professor of Urology, Faculty of Medicine, Zagazig University
Prof. Magdy S. El-Bahnasawy, MD Professor of Urology, Faculty of Medicine, Mansoura University
Ass. Prof. Mohammed Abdel-Rassoul, MD Assistant Professor of Urology, Faculty of Medicine, Cairo University
Ass. Prof. Mamdouh M. El-Hawy MD Assistant Professor of Urology, Faculty of Medicine, Minia University
Ass. Prof. Mamdouh M. El-Hawy MD Assistant Professor of Urology, Faculty of Medicine, Minia University
Dr. Khaled Mohyelden, MD Lecturer of Urology, Faculty of Medicine, Fayoum University
Contents
- XIII.1 List of Abbreviations
- XIII.2 Abstract
- XIII.3 Introduction:
- XIII.4 Methodology
- XIII.5 Erectile dysfunction:
- XIII.6 Premature Ejaculation
- XIII.7 Delayed Ejaculation
- XIII.8 Peyronie’s Disease
- XIII.9 Priapism
- XIII.10 Conclusions:
- XIII.11 References:
XIII.1 List of Abbreviations
- AUA American Urological Association
- AIPE Arabic Index of Premature Ejaculation
- BSSM British Society for Sexual Medicine
- CCH Clostridium Collagenase
- CDU Color Duplex Ultrasonography
- ED Erectile Dysfunction
- EMA European Medicines Agency
- EUA European Urological Association
- ISSM International Society of Sexual Medicine
- IHD Ischaemic Heart Disease
- NPT Nocturnal penile tumescence
- PP Penile Prosthesis
- PE Premature Ejaculation
- PEDT Premature Ejaculation Diagnostic Tool
- PSA Prostate-Specific Antigen
- QoL Quality of Life
- RP Radical Prostatectomy
- RT Radiotherapy
- SCs Stem Cells
- TA Tunica Albuginea
- VED Vacuum Erection Device
XIII.2 Abstract
XIII.2.1 Objectives:
XIII.2.2 Methods:
• Four international guidelines namely European Urological Association [EUA], American Urological Association [AUA], British Society for Sexual Medicine [BSSM], International Society of Sexual Medicine [ISSM];
• A panel of 8 high-caliber urologists and andrologists representing different universities, institutions and private practice in Egypt.
• A systematic literatures search was conducted using PubMed, Embase, and the Cochrane Library for English-language journal articles between January 2000 and January 2020, using the terms, “erectile dysfunction” (ED), “ejaculatory dysfunction”, “low sexual desire”, “Peyronie’s disease” “hypogonadism” and “priapism”.
• Criteria included all pertinent review articles, randomized controlled trials with tight methodological design, cohort studies, and retrospective analyses. We also manually reviewed references from selected articles.
XIII.2.3 Results:
XIII.2.4 Conclusion:
XIII.3 Introduction:
Erectile dysfunction (ED) and premature ejaculation (PE) are the two main complaints in male sexual medicine in the Middle East (1-2). Pharmacological therapies have completely changed the diagnostic and therapeutic approach to ED (3,4). The prevalence of ED is 20–90% among patients with different risk factors and medical comorbidities in Arab region countries. The high prevalence of severe ED in patients in this region could be attributed to:
1. The high prevalence of risk factors;
2. The poor control of those risk factors;
3. The delay in seeking medical advice; and
4. The non-compliance with treatment (1-2).
Unfortunately, in Arab countries there are no firm data on the true prevalence of sexual dysfunction. This prompted several investigators in the region to conduct research to identify the magnitude of the current problem (1-2).
This article integrates recent international guidelines with local experience and also highlights the apparent lack of congruency between available treatment and communication, cultural, and gender norms of Middle East populations that may inhibit treatment seeking. We clarified in our recent publication that strategies for diagnosis and treatment should consider the sociocultural-factors that influence diagnosis and treatment seeking and engagement behaviors necessary for successful outcomes. Specifically, the detrimental effects of sexual problems on quality of life and the potential benefits of proper diagnosis and treatment should be more widely communicated in order to diminish the social disgrace associated with sexual problems and their management (5).
XIII.4 Methodology
XIII.4.1 Resources of Recommendations:
Our recommendations are based on 4 resource categories:
o Four international guidelines and recommendations, namely European Urological Association [EUA], American Urological Association Guidelines [AUA], British Society for Sexual Medicine [BSSM], International Society of Sexual Medicine [ISSM], (6-12).
o Review of several guides, reviews, statements, recommendations, standards (10-14).
o Relevant Egyptian publications.
o A panel of 8 high-caliber urologists and andrologists representing different universities, institutions and private practice in Egypt.
XIII.4.2 Strength of clinical practice recommendation:
XIII.4.3 Synthesis of Recommendations:
XIII.5 Erectile dysfunction:
XIII.5.1 Definition:
XIII.5.2 Epidemiology:
XIII.5.2.1 General population:
XIII.5.2.2 Egypt and Arabic countries:
Shaeer and Shaeer explored epidemiological aspects of male sexuality using an online survey. They found that among Arab-speaking Internet users, the overall prevalence of ED was 45.1%, strongly correlating with various risk factors (18). In another study from Upper Egypt, Zedan et al., showed that of 658 men with ED, 17.3% had hypertension, 21.4% had DM and 40.1% were smokers (19).
In a cross-sectional community-based random sample of Egyptian men, Seyam et al., found that men with complete ED comprised 13.2% of the sample, 26% of men in their 50s, 49% of men in their 60s and 52% of those aged ⩾70 years (20).
XIII.5.3 Pathophysiology:
XIII.5.4 Diagnostic evaluation:
15. 1. A detailed medical and psycho-sexual history
16. 2. A thorough physical examination; and
17. 3. Appropriate laboratory tests (complete blood count, fasting glucose, lipid profile, kidney function, testosterone, and others if indicated) (24-27). For a satisfactory and cost-effective treatment, the evaluation methods should answer these inquiries:
18. 1. Whether the cause of ED is organic or psychogenic;
19. 2.The severity and possible reversibility of ED; 20. 3. The patient’s and probably the partner’s goals and expectations (24).
XIII.5.5 Basic work-up.
XIII.5.5.1 Sexual history:
The sexual history must include information about onset and duration of the erectile problem, prior surgeries, medications, family history of vascular disease, and substance use, and previous consultations and treatments. The presence of nocturnal and/ or morning erections suggests a psychogenic component to ED symptoms (33).
XIII.5.5.2 Physical examination:
A careful neurological examination should also be conducted. Testing for genital and perineal sensation and the bulbocavernosus reflex is also useful in assessing possible neurogenic ED (6-8,33). Kamel et al., compared penile measurements in normal subjects and patients with ED. The average fully stretched penile length in normal men was 12.9 cm, but was 11.2 cm in patients with ED (significantly different, P < 0.001), although the mean fully stretched penile girths were not statistically different between the groups (34).
A history and physical examination had 95% sensitivity but only 50% specificity in diagnosing organic ED. In many cases, a careful history and physical examination will direct the physician to the most expedient and cost-effective approach, and eliminate the need for unnecessary diagnostic tests (35).
XIII.5.5.3 Laboratory testing:
Laboratory evaluation includes fasting blood glucose, HbA1c, lipid profile if they have not recently been assessed, renal function, a complete blood count, urine analysis, should be done in the initial evaluation. Hormonal tests and additional laboratory tests may be considered in selected patients e.g., prostate-specific antigen (PSA), FSH and LH (36,37).
El-Sakka et al. reported a possible association between sexual dysfunction, e.g. ED, premature ejaculation (PE) and low desire, and hypogonadism. They also found that 23.8% of patients had endocrinopathy. There were significant associations between low desire and low testosterone level, hyperprolactinaemia and hypothyroidism (P < 0.05 for each). Furthermore, they investigated the effect of testosterone replacement therapy on the PSA level in hypogonadal men with ED (38,39). Zohdy et al. concluded in their study that obesity is associated with lower total testosterone levels and disturbances of penile haemodynamics (40).
XIII.5.5.4 Specialized diagnostic tests:
XIII.5.5.5 Psychiatric assessment:
Indications for specific diagnostic tests (6-8)
o Primary ED (not caused by organic disease or psychogenic disorder).
o Young patients with a history of pelvic or perineal trauma, who could benefit from potentially curative revascularization surgery or angioplasty
o Patients with penile deformities which might require surgical correction (e.g., Peyronie’s disease, congenital penile curvature
o Patients with complex psychiatric or psychosexual disorders.
o Patients with complex endocrine disorders.
o Specific tests may be indicated at the request of the patient or his partner.
o Medico-legal reasons (e.g., implantation of penile prosthesis to document end stage ED, sexual abuse).
XIII.5.5.6 Recommendations for the diagnosis of ED:
Recommendations |
Strength Rate |
---|---|
XIII.5.6 Treatment of ED
XIII.5.6.1 Non-surgical treatment of ED:
XIII.5.6.2 Conservative treatment
The interest in PDE5Is as targets for pharmacologic treatment has evolved with the development of selective PDEIs (51). The effectiveness and tolerability of 12 weeks of open-label treatment with sildenafil citrate for erectile dysfunction (ED) associated with a diagnosis of diabetes mellitus and/or hypertension were assessed in clinical practice in three Middle Eastern countries (52). Furthermore, interesting data add to the body of knowledge regarding testosterone level and sexual function and suggested that testosterone level play a role in sexual desire, frequency of nocturnal erection and frequency of intercourse, further approximately 20 % of men with complains of sexual dysfunction have hypogonadism (53). Makhlouf et al shows that both conditions are fairly prevalent in an ED clinic population, and that there is increased likelihood of finding depression among men with hypogonadism (54).
Early treated rats with vardenafil had preserved erection and normal cavernosal structure, ultrastructure and gene expression of iNOS, nNOS, eNOS, and TGF-β1. Clinical application of this result may encourage early administration of PDE5I (55). Recent study had shown that single intracavernosal dose of Botox either 50 or 100 U in my be of benefit in PDE5I non responders in patients with vasculogenic ED (56).
Several studies have established the role of ICI of vasoactive materials as a very common alternative tool in treatment of severe ED particularly in diabetic patients, post-RP, PDE5I non-responders. Further, new studies have denoted the potential future role of intracavernosal treatment for ED in the era of stem cells and gene therapy. ICI of vasoactive material continues to be a highly effective and safe treatment tool for men with wide varieties of ED etiologies. Several experimental and clinical studies are currently investigating new ICI materials. Hopefully in the near future, we might witness evolved molecules and innovative strategies that could help to treat ED patients with different etiologies (57).
Recommendations |
Strength Rate |
---|---|
Recommendations |
Strength Rate |
---|---|
Recommendations |
Strength Rate |
---|---|
XIII.5.6.2.1.4 Recommendations for men with Erectile Dysfunction and hypogonadism
Recommendations |
Strength Rate |
---|---|
XIII.5.6.2.1.5 Recommendations for PDE5Is failure in patients with ED
Recommendations |
Strength Rate |
---|---|
XIII.5.6.2.1.6 Recommendations for ED treatment with a vacuum erection device (VED)
Recommendations |
Strength Rate |
---|---|
XIII.5.6.2.1.7 Recommendations for the use of ICI therapy
Recommendations |
Strength Rate |
---|---|
XIII.5.6.2.1.8 Recommendations for intracavernosal stem cell therapy.
Recommendations |
Strength Rate |
---|---|
XIII.5.6.3 Surgical treatment for ED
XIII.5.6.3.1 Vascular surgery
According to the current literature, the following inclusion criteria should be met when selecting patients for arterial surgery (59):
o Age less than 55 years,
o Cessation of tobacco smoking,
o Nondiabetic
o Absence of venous leakage
o Radiographic confirmation of focal stenosis of the internal pudendal artery.
o No atherosclerosis
o Usually result from perineal or pelvic trauma
Several Arterial revascularization procedures have been described to create arterial inflow to the corpora, similarly creating an anastomosis of the inferior epigastric artery either to the corpus cavernosum directly or to vascular conduits of the penis such as the dorsal artery (i.e., revascularization), the deep dorsal vein (i.e., arterialization), or the deep dorsal vein with venous ligation (i.e., arterialization with venous reconstruction) (59). Complications of arterial revascularization surgery include glans hyperemia (13%), shunt thrombosis (8%), and inguinal hernias (6.5%) (60).
Previous studies reported outcomes for arterial reconstruction procedures, the most commonly used outcome measure was the percentage of men in different response categories post-surgery. Typically, high response rates (complete or partial) were reported at short intervals post-surgery, with declining rates over time. Overall, there was considerable variability regarding response rates, particularly complete (range 12 to 81.6%) and partial response rates (range 7.7 to 53.3%) (6-8).
1. Are not suitable for different pharmacotherapies or prefer a definitive therapy; and,
2. Do not respond to pharmacological therapies (62).
Men and their partners should be thoroughly counseled regarding the benefits and potential risks of this modality of treatment to ensure appropriate choice of device, realistic post-operative expectations, and high levels of satisfaction (63).
The two currently available classes of penile implants include inflatable (2- and 3-piece) and semirigid devices (malleable, mechanical, soft flexible) (64,65).
There are two main surgical approaches for inflatable penile prosthesis implantation: penoscrotal and infrapubic (64,65). Regardless of the indication, prosthesis implantation has one of the highest satisfaction rates (92-100% in patients and 91-95% in partners) among the treatment options for ED based on appropriate consultation (66). There is sufficient evidence to recommend this approach in patients not responding to less-invasive treatments due to its high efficacy, safety and satisfaction rates (67). There are also currently no head to head studies comparing the different manufacturers’ implants, demonstrating superiority of one implant type over another.
Complications of penile prostheses
The two main complications of penile prosthesis implantation are mechanical failure and infection. Careful surgical techniques with proper antibiotic prophylaxis against Gram-positive and Gramnegative bacteria reduces infection rates to 2-3% with primary implantation in low-risk patients and in high volume centers (68). Higher-risk populations include patients undergoing revision surgery, those with impaired host defenses (immunosuppression, diabetes mellitus, spinal cord injury) or those with penile corporal fibrosis (69).
XIII.5.6.3.2 Recommendations for Surgical management of erectile dysfunction.
Recommendations |
Strength Rate |
---|---|
XIII.6 Premature Ejaculation
XIII.6.1 Definition:
Two more PE syndromes have been proposed: ‘Variable PE’ is characterized by inconsistent and irregular early ejaculations, representing a normal variation in sexual performance. ‘Subjective PE’ is characterized by subjective perception of consistent or inconsistent rapid ejaculation during intercourse, while ejaculation latency time is in the normal range or can even last longer. It should not be regarded as a symptom or manifestation of true medical pathology. The addition of these new types may help in overcoming the limitations of each individual definition and it may support a more flexible view of PE for patient stratification, diagnosis and treatment
XIII.6.2 EPIDEMIOLOGY
XIII.6.3 Recommendation for Assessment of PE
Recommendations |
Strength Rate |
---|---|
XIII.7 Delayed Ejaculation
XIII.7.1 Definition:
XIII.7.2 Background:
Of all the male sexual dysfunctions, DE is the least understood, least common and least studied (78). Lack of consistent definition and overlap with other dysfunctions such as anejaculation or anorgasmia adds to the difficulty of understanding, diagnosis and management. There is currently no single gold standard for diagnosing DE; the history is the keypoint for the diagnosis. Post-coital urine analysis for sperms to exclude retrograde ejaculation is a strong adjunct for the diagnosis. If applicable treatment should be cause-specific. There are different approaches for its management, including psychosexual interventions, drug therapy, and specific measures for patients with SCI and infertile men. Several drugs were used for treatment of DE however no single drug was approved. Currently, no drug has been approved by FDA for DE. Successful drug treatment of DE is still in its infancy (79). For namely spinal cord injuries (SCI) and refractory cases seeking fertility penile vibratory stimulation (PVS) or electo-ejaculation (EE) were applied with good success rates of semen retrieval. Otherwise different epididymal or testicular sperm extraction methods were applied for IVF/ICSI.
XIII.7.3 Recommendations for assessment of DE
Recommendations |
Strength Rate |
---|---|
XIII.7.4 Recommendations for the treatment of DE
Recommendations |
Strength Rate |
---|---|
XIII.8 Peyronie’s Disease
XIII.8.1 EPIDEMIOLOGY
XIII.8.2 PATHOPHYSIOLOGY
XIII.8.3 PATIENT EVALUATION
Physical examination should include genital examination, such as plaque size and site, multiplicity as well as assessment of the degree of penile deformity based on clinical assessment and selfphotography. An in-office intracavernosal injection of a vasoactive agent test is recommended before invasive intervention. Penile CDU provides an objective assessment of various PD characteristics especially calcified plaques and vascular flow parameters. Routine use of plain radiography, computed tomography, and magnetic resonance imaging are not recommended.
XIII.8.4 MANAGEMENT OF PD
XIII.8.4.1 Non-operative treatment
XIII.8.4.2 Operative treatment
Penile prosthesis should be considered in men with complex penile deformities and refractory erectile dysfunction.
XIII.8.5 Recommendations for evaluation of PD:
Recommendations |
Strength Rate |
---|---|
XIII.8.6 Recommendations for the non-operative treatment of PD
Recommendations |
Strength Rate |
---|---|
XIII.8.7 Recommendations for Surgical treatment
Recommendations |
Strength Rate |
---|---|
XIII.9 Priapism
XIII.9.1 Definition:
XIII.9.2 Pathophysiology:
XIII.9.3 Types of Priapism:
• Ischemic priapism "veno-occlusive"
It is a persistent erection within corpora cavernosa and no or little cavernous arterial flow. The patient typically complains of penile pain and clinical examination reveals a rigid erection.
• Non-ischemic priapism
It is a persistent erection caused by increased cavernous arterial inflow. The patient typically reports an erection that is not fully rigid and is not associated with pain.
• Stuttering (recurrent or intermittent) priapism
It is a distinct condition that characterized by recurrent attacks of painful and prolonged erections. They are often self-limited with intervening periods of detumescence.
• Primary/Secondary
XIII.9.4 Diagnosis
XIII.9.4.1.1 Clinical History:
XIII.9.4.1.1.1 Physical examination:
In ischemic priapism, both corpora cavernosae are usually rigid and tender while non-tender, partially tumescent corpora cavernosa suggest a non-ischemic priapism. Abdominal, perineal, and rectal examinations may help in diagnosing pelvic trauma, infection or malignancy, also full neurologic exam maybe needed in patients with spinal cord injury or lesions (92,93).
XIII.9.4.1.2 Laboratory investigations:
Reticulocyte counts and hemoglobin electrophoresis may signify the presence of Sickle cell disease/trait or other hemoglobinopathies. Cavernous blood gas aspiration and analysis allows immediate differentiation between the variants of priapism (92-94).
Clinical History, Physical Examination, Laboratory Investigations and Radiologic Assessment in Different Types of Priapism are shown in below table (95).
Variant |
History and clinical examination |
Penile blood appearance |
Penile blood gas findings |
Color Duplex ultrasonography findings |
---|---|---|---|---|
Ischemic priapism |
Tender and rigid corpora cavernosa |
Corpus cavernosum testing: blood is hypoxic and dark in color |
pO2> 30 mmHg pCO2>60 mmHg pH< 7.25 |
Minimal or absent blood flow |
Nonischemic priapism |
Perineal or penile trauma; non tender, partially tumescent corpora cavernosa |
Corpus cavernosum testing: blood is oxygenated and red |
pO2< 90 mmHg pCO2 < 40 mmHg pH=7.4 similar to normal arterial blood) |
Blood flow is normal to high in velocity |
Stuttering (recurrent) priapism |
Similar attacks |
Corpus cavernosum testing: blood is hypoxic and dark in color |
Blood gases: pO2< 30 mmHg; pCO2>60 mmHg pH < 7.25 |
Minimal or absent blood flow during acute priapism; normal blood flow otherwise |
XIII.9.4.1.3 Radiologic assessment:
Penile MRI allows good judgment on smooth muscle viability within the corpora after episodes of priapism. It also helps in detecting malignant infiltration and segmental cavernosal thrombosis. Drawbacks of this technique include costs, MRI accessibility of and the time consumption (92,95).
XIII.9.4.1.4 Recommendations for diagnosis of ischemic priapism
Recommendations |
Strength Rate |
---|---|
XIII.9.5 Management of Priapism
XIII.9.5.1 Ischemic Priapism:
XIII.9.5.1.1 Non-surgical management
Drugs used ICI treatment include: Epinephrine (adrenaline) 2 ml of 1/100,000 adrenaline solution up to five times over a twenty-minute period, Nor-epinephrine (nor adrenaline) 10–20 mcg [as occasion requires], Ephedrine: 50–100 mg [as occasion requires] and Phenylephrine (preferable agent) 200 μg every three to five minutes with a maximum dosage is 1 mg within one hour (92-95). Lower doses are recommended in children and patients with severe cardiovascular disease.
Administration of α-adrenergic agonists is contraindicated in patients who have malignant or poorly controlled hypertension or are concurrently using monoamine oxidase inhibitors. In these patients, early surgical intervention may be necessary.
For priapism specifically related to SCD, medical therapies such as intravenous hydration, oxygenation, alkalinization, and exchange transfusion maybe performed.
However, these interventions should never precede the first-line treatment for all episodes of ischemic priapism mentioned above. Ischemic priapism of extended durations (typically greater than 48 h) is unlikely to resolve with ICI/irrigation therapy alone, therefore these patients may be counseled to consider more immediate surgical intervention (92-95).
XIII.9.5.1.2 Surgical shunts
Distal shunts |
Percutaneous distal shunts |
||
---|---|---|---|
Open distal shunt |
|||
Proximal shunts |
Open proximal shunt |
||
Corporo saphenous vein or superficial/deep dorsal vein shunts |
|||
XIII.9.5.2 Penile prosthesis (PP)
XIII.9.5.3 Recommendations for the Treatment of Ischemic Priapism:
Recommendations |
Strength Rate |
---|---|
XIII.9.5.4 Recommendations for the treatment of non-ischemic priapism
Recommendations |
Strength Rate |
---|---|
XIII.9.5.5 Recommendations for the treatment of Stuttering Priapism
Recommendations |
Strength Rate |
---|---|
XIII.10 Conclusions:
XIII.11 References:
1- El-Sakka AI. Erectile dysfunction in Arab countries. Part I: Prevalence and correlates. Arab Journal of Urology (2012) 10, 97–103
2- El-Sakka AI. Characteristics of erectile dysfunction in Saudi patients. Int J Impot Res 2004; 16:13– 20.
3- Lindau, S.T., et al. A study of sexuality and health among older adults in the United States. N Engl J Med, 2007. 357: 762. https://www.ncbi.nlm.nih.gov/pubmed/17715410
4- Rosenberg, M.T., et al. Identification and diagnosis of premature ejaculation. Int J Clin Pract, 2007. 61: 903. https://www.ncbi.nlm.nih.gov/pubmed/17504352
5- El-Sakka A. I. Middle East Cultural Barriers and the Treatment of Sexual Problems. In ., Cultural Differences and the Practice of Sexual Medicine, “Trends in Andrology and Sexual Medicine” (eds). Springer Science + Business Media, Chapter 8 , P 135-148. 2020
6- K. Hatzimouratidis, F. Giuliano, I. Moncada, A. Muneer, A. Salonia, P. Verze, A. Parnham, E.C. Serefoglu: European Association of Urology (EAU) Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism, 2018
7- European Association of Urology (EAU), Pocket Guidelines edition, 2019
8- Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh J, Khera M, McVary KT, Miner MM, Nelson CJ, Sadeghi-Nejad H, Seftel AD, Shindel AW . Erectile Dysfunction: AUA Guideline. J Urol. 2018 Sep;200(3):633-641. doi: 10.1016/j.juro.2018.05.004. Epub 2018 May 7.
9-Hackett G, Kirby M, Wylie K, Heald A, Ossei-Gerning N, Edwards D, Muneer A. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017. J Sex Med. 2018 Apr;15(4):430-457. doi: 10.1016/j.jsxm.2018.01.023. Epub 2018 Mar 14.
10-Hackett G et al. The British Society for Sexual Medicine guidelines on adult testosterone deficiency with statements for UK practice. J Sex Med 2017; 14:1504-23.
11-ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN. Version: September 2015, International Society for Sexual Medicine - www.issm.info
12-ISSM QUICK REFERENCE GUIDE TO PE. Version: January 2015 International Society for Sexual Medicine - www.issm.info
13- Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR; AACE Reproductive Endocrinology Scientific Committee.. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF TESTOSTERONE AND CARDIOVASCULAR RISK. Endocr Pract. 2015 Sep;21(9):1066-73. doi: 10.4158/EP14434.PS
14- Fode M, Salonia A, Minhas S, Burnett AL, Shindel AW. Late-onset Hypogonadism and Testosterone Therapy - A Summary of Guidelines from the American Urological Association and the European Association of Urology. Eur Urol Focus. 2019 Jul;5(4):539-544. doi: 10.1016/j.euf.2019.02.021. Epub 2019 Mar 8.
15- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA, 1993. 270: 83.
16- Jian-Kang Chao, Thomas I-Sheng Hwang: Mini review, Contemporary management of erectile dysfunction. Urological Science 24 (2013) 35-40.
17- El-Sakka A. I. Association of Risk Factors and Medical Co-Morbidities with Male Sexual Dysfunctions. J Sexual Med; 4:1691–1700, 2007.
18- Shaeer O, Shaeer K. The Global Online Sexuality Survey (GOSS). Erectile dysfunction among Arabic-speaking Internet users in the Middle East. J Sex Med 2011;8:2152–60.
19- Zedan H, Hareadei AA, Abd-Elsayed AA, Abdel-Maguid EM. Cigarette smoking, hypertension and diabetes mellitus as risk factors for erectile dysfunction in upper Egypt. East Med Health J 2010;16:281–5.
20- Seyam RM, Albakry A, Ghobish A, Arif H, Dandash K, Rashwan H. Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study. Int J Impot Res 2003;15:237– 45.
21- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54– 61. https://www.ncbi.nlm.nih.gov/pubmed/8254833
22- Dong, J.Y., et al. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol, 2011. 58: 1378.
23- El-Sakka AI, Morsy AM, Fagih BI, Nassar AH. Coronary artery risk factors in patients with erectile dysfunction. J Urol 2004; 172:251–4.
24- El-Sakka AI. Erectile dysfunction in Arab countries. Part II: Diagnosis and treatment. Arab Journal of Urology (2012) 10, 104–109
25- Lue TF. A patient’s goal-directed approach to erectile dysfunction and Peyronie’s disease. Can J Urol 1995;2(Suppl. 1):13–7.
26- El-Sakka AI, Lue TF. A rational approach to investigation of the sexually dysfunctional man. In Morales A ed. Erectile Dysfunction: Issues in Current Pharmacotherapy. Martin Dunitz, 1998; 49– 69.
27- Lue TF, El-Sakka AI. Erectile dysfunction. In: Weiss RM, George NJR, O’Reilly PH, editors. Comprehensive Urology. London, UK: Mosby Harcourt Sciences; 2001. p. 597–612.
28- Hatzichristou, D., et al. Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires. J Sex Med, 2016. 13: 1166.
29- Mulhall JP, Goldstein I, Bushmakin AG et al: Validation of the erection hardness score. J Sex Med 2007; 4: 1626.
30- Rosen RC, Cappelleri JC, Smith MD et al: Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319
31- R Shamloul, H Ghanem and A Abou-zeid: Validity of the Arabic version of the sexual health inventory for men among Egyptians. International Journal of Impotence Research (2004) 16, 452– 455.
32- Abdelrahman Elnashar, Amr M. Gadallah, Alaa A. Abdelaal, et al., Can the International Index of Erectile Function (IIEF-5) be used as a diagnostic tool to the severity of vasculogenic erectile dysfunction?. Middle East Fertility Society Journal (2012) 17, 101–104.
33- Arthur L. Burnett, Ajay Nehra, Rodney H. Breau,et al., Erectile Dysfunction: AUA Guideline. J Urol, Vol. 200, 633-641, September 2018.
34-Kamel I, Gadalla A, Ghanem H, Oraby M. Comparing penile measurements in normal and erectile dysfunction subjects. J Sex Med 2009; 6:2305–10.
35- Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995; 45:498–502.
36- Heidenreich, A., et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol, 2014. 65: 124.
37- Maggi, M., et al. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med, 2013. 10: 661.
38- El-Sakka AI, Hassoba HM, Sayed HM, Tayeb KA. Pattern of endocrinal changes in patients with sexual dysfunction. J Sex Med 2005; 2:551–8.
39- El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med 2005; 2:235–40
40- Zohdy W, Kamal EE, Ibrahim Y. Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction. J Sex Med 2007; 4:797–808.
41- Hatzichristou, D.G., et al. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol, 1998. 159: 1921.
42- R Seyam, K Mohamed, A Al Akhras and H Rashwan: A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. International Journal of Impotence Research (2005) 17, 346–353
43- Sikka, S.C., et al. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med, 2013. 10: 120. https://www.ncbi.nlm.nih.gov/pubmed/22970798
44- El-Sakka AI, Morsy AM. Screening for ischemic heart disease in patients with erectile dysfunction. The role of penile Doppler ultrasonography. Urology 2004; 64:346–50
45- El-Sakka AI. Penile axial rigidity and Doppler ultrasonography parameters in patients with erectile dysfunction: association with type 2 diabetes. Urology. 2003 Sep;62(3):525-31
46- Goldstein I, Auerbach S, Padma-Nathan H, et al.,: Axial penile rigidity as primary efficacy outcome during multi-institutional in-office dose titration clinical trials with alprostadil alfadex in patients with erectile dysfunction. Int J Impot Res; 12: 205-11, 2000
47- El-Sakka AI. Association between International Index of Erectile Function and axial penile rigidity in patients with erectile dysfunction. Int J Impot Res. 2003 Dec;15(6):426-9
48- Wang, T.D., et al. Clinical and Imaging Outcomes up to 1 Year Following Balloon Angioplasty for Isolated Penile Artery Stenoses in Patients With Erectile Dysfunction: The PERFECT-2 Study. J Endovasc Ther, 2016. 23: 867.
49- Capogrosso, P., et al. One patient out of four with newly diagnosed erectile dysfunction is a young man--worrisome picture from the everyday clinical practice. J Sex Med, 2013. 10: 1833.
50--Ahmed I El-Sakka. Pharmacotherapy for erectile dysfunction in diabetic malesn Expert Opinion on Pharmacotherapy 19(4):1-12 · August 2018.
51-Allen D Seftel MD ,Mamdouh Ab Mohammed MD, Stanley E Althof PhD.Erectile dysfunction: etiology, evaluation, and treatment options. Medical Clinics of North America .Volume 88, Issue 2, March 2004, Pages 387-416.
52-El-Sakka AI1, Anis T, Khadr N, Ismail TA, Hegazy AM, Fekry O, Youseif E.Sildenafil for erectile dysfunction in the Middle East: observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting. J Int Med Res. 2011;39(2):558-68
53-Mohamed M.Seftel AD.Althof S.et al. Office evaluation of male sexual dysfunction : detection of hypogonadism ,depression and erectile dysfunction [abstract 1261J Urol 2003;supple:169.
54-A A Makhlouf, M A Mohamed, A D Seftel & C Neiderberger. Hypogonadism is associated with overt depression symptoms in men with erectile dysfunction.International Journal of Impotence Research volume 20, pages 157–161 (2008).
55-Ismail EA1, Younis SE2, Ismail IY1, El-Wazir YM3, El-Sakka AI1.Early administration of phosphodiesterase 5 inhibitors after induction of diabetes in a rat model may prevent erectile dysfunction. Andrology. 2020 Jan;8(1):241-248.
56-Ghanem H, Raheem AA, Abdel Rahman IFS, Johnson M, Abdel- Raheem T. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev 2018;6(1):135– 42. doi:10.1016/j.sxmr.2017.07.008.
57- Ahmed I El-Sakka. What is the current role of intracavernosal injection in management of erectile dysfunction. International journal of impotence research 28(3) · April 2016.
58- Babaei, A.R., M.R. Safarinejad, and A.A. Kolahi, Penile revascularization for erectile dysfunction: a systematic review and meta-analysis of effectiveness and complications. Urol J, 2009. 6(1): p. 17.
59- Hellstrom, W.J., et al., Implants, mechanical devices, and vascular surgery for erectile dysfunction. J Sex Med, 2010. 7(1 Pt 2): p. 501-23.
60- Kawanishi, Y., et al., Penile revascularization surgery for arteriogenic erectile dysfunction: the long-term efficacy rate calculated by survival analysis. BJU Int, 2004. 94(3): p. 361-8.
61- Sohn, M., et al., Standard operating procedures for vascular surgery in erectile dysfunction: revascularization and venous procedures. J Sex Med, 2013. 10(1): p. 172-9.
62- Antonini, G., et al., Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications. Int J Impot Res, 2016. 28(1): p. 4-8.
63- Kramer, A.C. and A. Schweber, Patient expectations prior to coloplast titan penile prosthesis implant predicts postoperative satisfaction. J Sex Med, 2010. 7(6): p. 2261-2266.
64- Montague, D.K., Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am, 2011. 38(2): p. 217-25.
65- Mulcahy, J.J., et al., The penile implant for erectile dysfunction. J Sex Med, 2004. 1(1): p. 98-109.
66- Natali, A., R. Olianas, and M. Fisch, Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. J Sex Med, 2008. 5(6): p. 1503-12.
67- Akakpo, W., M.A. Pineda, and A.L. Burnett, Critical Analysis of Satisfaction Assessment After Penile Prosthesis Surgery. Sex Med Rev, 2017. 5(2): p. 244-251.
68- Carson, C.C., J.J. Mulcahy, and F.E. Govier, Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol, 2000. 164(2): p. 376-80.
69- Henry, G.D., et al., An outcomes analysis of over 200 revision surgeries for penile prosthesis implantation: a multicenter study. J Sex Med, 2012. 9(1): p. 309-15.
70- Serefoglu, E.C., et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med, 2014. 11: 1423.
71- Waldinger, M.D., et al. The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSM-V. J Sex Med, 2008. 5: 1079.
72- cMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies–part I–defining and selecting the study population. J Sex Med. 2008;5(8):1805–1816.
73- Arafa M, Shamloul R. Development and validation of the Arabic Index of Premature Ejaculation (AIPE). J Sex Med. 2007; 4:1750–1756.
74- El-Sakka AI. Association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med. 2007;4(6):1691–1700.
75- El-Sakka AI. Severity of erectile dysfunction at presentation: effect of premature ejaculation and low desire. Urology. 2008;71(1):94–98.
76- Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014;11(6):1392–1422
77-American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
78-Abdel-Hamid IA and Ali OI: Delayed Ejaculation: Pathophysiology, Diagnosis, and TreatmentWorld J Mens Health 2018 January 36(1): 22-40. 79-Abdel-Hamid IA, Elsaied MA and Mostafa T. The drug treatment of delayed ejaculationTransl Androl Urol 2016;5(4):576-591. 80- Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze A. European Association of Urology. EAU pocket guidelines on penile curvature. Eur Urol 2019;231-8. 81- AUA guideline on Peyronie’s disease. Available at: https://www. auanet.org/education.guidelines/Peyronie’s-disease.cfm. 82- Chung E, Ralph D, Kagioglu A, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med 2016; 13:905e923. 83- El-Sakka AI. Prevalence of Peyronie’s disease among patients with erectile dysfunction. Eur Urol 2006; 49:564-9. 84- El-Sakka AI, Tayeb KA. Vascular impairment of erection in patients with diabetes and Peyronie's disease: is that accumulative? J Sex Med. 2009 Jun;6(6):1736-1742 85- Arafa M, Eid H, El-Badry A, et al. The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res 2007; 19:213-7 86- Devine, C.J., Jr., et al. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol, 1997. 157: 285.https://www.ncbi.nlm.nih.gov/pubmed/26907743 87- Gonzalez-Cadavid, N.F., et al. Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol, 2005. 2: 291. https://www.ncbi.nlm.nih.gov/pubmed/16474811 88- El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997 Oct;158(4):13914. 89- Carson CC, Levine LA. Outcomes of surgical treatment of Peyronie’s disease. BJU Int 2014; 113:704-13. 90- Lue TF, El-Sakka AI. Venous patch graft for Peyronie’s disease. Part I: Technique. J Urol 1998; 160:2047-9. 91- Yang D, Hatzichristodoulou K, Hebert J, etal. Multi-Center Experience Utilizing Collagen Fleece for Plaque Incision with Grafting to Correct Residual Curvature at Time of Inflatable Penile Prosthesis Placement in Peyronie's Disease Patients. J Sex Med 2020;17:S27-120. 92- Montague, D., Jarow, J., Broderick, G., Dmochowski, RR., Heaton, JP., Lue, TF. et al. (2003) American Urological Association guideline on the management of priapism. J Urol 170: 1318–
77-American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
78-Abdel-Hamid IA and Ali OI: Delayed Ejaculation: Pathophysiology, Diagnosis, and TreatmentWorld J Mens Health 2018 January 36(1): 22-40.
79-Abdel-Hamid IA, Elsaied MA and Mostafa T. The drug treatment of delayed ejaculationTransl Androl Urol 2016;5(4):576-591.
80- Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze A. European Association of Urology. EAU pocket guidelines on penile curvature. Eur Urol 2019;231-8.
81- AUA guideline on Peyronie’s disease. Available at: https://www. auanet.org/education.guidelines/Peyronie’s-disease.cfm.
82- Chung E, Ralph D, Kagioglu A, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med 2016; 13:905e923.
83- El-Sakka AI. Prevalence of Peyronie’s disease among patients with erectile dysfunction. Eur Urol 2006; 49:564-9.
84- El-Sakka AI, Tayeb KA. Vascular impairment of erection in patients with diabetes and Peyronie's disease: is that accumulative? J Sex Med. 2009 Jun;6(6):1736-1742
85- Arafa M, Eid H, El-Badry A, et al. The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res 2007; 19:213-7
86- Devine, C.J., Jr., et al. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol, 1997. 157: 285.https://www.ncbi.nlm.nih.gov/pubmed/26907743
87- Gonzalez-Cadavid, N.F., et al. Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol, 2005. 2: 291. https://www.ncbi.nlm.nih.gov/pubmed/16474811
88- El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997 Oct;158(4):13914.
89- Carson CC, Levine LA. Outcomes of surgical treatment of Peyronie’s disease. BJU Int 2014; 113:704-13.
90- Lue TF, El-Sakka AI. Venous patch graft for Peyronie’s disease. Part I: Technique. J Urol 1998; 160:2047-9.
91- Yang D, Hatzichristodoulou K, Hebert J, etal. Multi-Center Experience Utilizing Collagen Fleece for Plaque Incision with Grafting to Correct Residual Curvature at Time of Inflatable Penile Prosthesis Placement in Peyronie's Disease Patients. J Sex Med 2020;17:S27-120.
92- Montague, D., Jarow, J., Broderick, G., Dmochowski, RR., Heaton, JP., Lue, TF. et al. (2003) American Urological Association guideline on the management of priapism. J Urol 170: 1318– 1324.].
93-Bivalacqua, T. and Burnett, A. (2006) Priapism: new concepts in the pathophysiology and new treatment strategies. Curr Urol Rep 7: 497–502.
94- Lue, T., Hellstrom, W., McAninch, J. and Tanagho, E. (1986) Priapism: a refined approach to diagnosis and treatment. J Urol 136: 104–108.
95-Broderick, G., Kadioglu, A., Bivalacqua, T., Ghanem, H., Nehra, A. and Shamloul, R. (2010) Priapism: pathogenesis, epidemiology, and management. J Sex Med 7: 476–500.
96-Ralph, D., Garaffa, G., Muneer, A. Freeman, A., Rees, R., Christopher, AN. et al. (2009) The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol 56: 1033–1038.
97-Emad A. Salem and Ola El Aasser. Management of Ischemic Priapism by Penile Prosthesis Insertion: Prevention of Distal Erosion; The Journal Of Urology JUNE 2010. 183, 2300-2303
98- Faysal A. Yafi a , Wayne J.G. Hellstrom. Immediate Placement of Penile Prosthesis for the Management of Ischemic Priapism as First-line Treatment. E U R O P E A N U R O L O G Y F O C U S 5 (2 0 1 9) 5 3 1 – 5 3 2
99- Marco Capece 1, Roberto La Rocca 2, Vincenzo Mirone 2, Trinity J Bivalacqua 3, Fabio Castiglione 4, Maarten Albersen 5, David J Ralph 4, Asif Muneer 4, Giulio Garaffa. A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data?. Sex Med Rev 2019 Jul;7(3):530-534.